About
Nuclein, LLC is an Austin, Texas-based company founded in 2017 with a vision to enable simple, affordable, rapid, and accurate testing for everyone. Its DASH® Rapid PCR System runs the FDA-cleared and CLIA-waived DASH® SARS-CoV-2 & Flu A/B Test and delivers lab-quality, point-of-care PCR results in 15 minutes. With a speed that is typically only available with antigen tests, the DASH® Rapid PCR System was designed to offer low-cost, sensitive and specific results, with robust multiplexing across various sample types, and requires less than one minute of hands-on time. Nuclein has raised approximately $50 million to date, led by private equity firm Trinity Investors. In 2023, Nuclein merged with Minute Molecular Diagnostics, Inc., a Northwestern University spin-out that initially developed the DASH System.